CLINICAL ORAL IMPLANTS RESEARCH, cilt.22, sa.12, ss.1433-1439, 2011 (SCI-Expanded)
Objectives: The delivery of growth factors for enhanced osseointegration depends on the effectiveness of the carrier systems at the boneimplant interface. This study evaluated the effect of solo and dual delivery of recombinant human bone morphogenetic protein-2 (rhBMP-2) and recombinant human vascular endothelial growth factor (rhVEGF165) from biomimetically octacalcium phosphate-coated implants on osseointegration.